Want to see SLS full AI Analyst Report?

SELLAS Life Sciences Group (SLS) Price & Analysis

1,766 Followers

SLS Stock Chart & Stats

$14.09

-$1.02(-8.27%)

At close: Jul 24 4:00 PM EDT

$14.09

-$1.02(-8.27%)

Day’s Range― - ―

52-Week Range$1.39 - $15.88

Previous CloseN/A

Volume6.73M

Average Volume (3M)6.24M

Market Cap

$2.42B

Enterprise Value$2.65B

Total Cash (Recent Filing)$138.44M

Total Debt (Recent Filing)$737.00K

Price to Earnings (P/E)―

Beta0.73

Next Earnings

Nov 18, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding201,945,710

10 Day Avg. Volume6,298,990

30 Day Avg. Volume6,238,145

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)5.80

Price to Sales (P/S)0.00

P/FCF Ratio-14.48

Enterprise Value/Market Cap1.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-104.60

Forecast

1Y Price Target

$30.00

Price Target Upside112.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.21

Revenue Forecast (FY)$36.13M

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal debt materially reduces solvency and interest-burden risk while giving SELLAS greater flexibility to prioritize clinical development. The repaired equity position also provides a stronger financial base than in 2023, although ongoing losses may still require future financing.

Focused Oncology Immunotherapy PipelineSELLAS has a focused development strategy built around immune responses to tumor-associated antigens, with two named candidates and applications across multiple cancer indications. If clinical evidence supports efficacy, this concentration could create repeatable development expertise and several potential routes to value creation.

GPS Commercial License FrameworkThe Greater China license gives GPS an external commercialization pathway and preserves contractual milestone potential without requiring SELLAS to conduct all regional commercialization itself. This creates a possible future source of non-product revenue tied to development, regulatory, and commercial progress.

Bears Say

No Current Commercial RevenueSELLAS has not established recurring commercial revenue, leaving its financial profile dependent on clinical progress rather than an operating business with proven sales. Persistent losses alongside zero recent revenue make earnings recovery highly dependent on successful approvals and commercialization.

Persistent Cash Burn And Financing DependenceMaterial negative operating and free cash flow show that the company converts its equity base into ongoing research and operating expenditure rather than internally generated cash. Continued burn increases dependence on external capital and can constrain development plans or create dilution risk.

Adverse Arbitration OutcomeThe arbitration loss removes a favorable legal outcome as a source of near-term support and imposes an additional cash cost. It also increases uncertainty around the disputed GPS arrangement, even though the existing Greater China license and potential milestones remain in place.

SELLAS Life Sciences Group News

Sellas Life Sciences falls -13.1%

Sellas Life Sciences (SLS) is down -13.1%, or -$1.49 to $9.85. Published first on TheFly – the ultimate...

7d ago

SLS

Sellas Life Sciences falls -12.5%

Sellas Life Sciences (SLS) is down -12.5%, or -$1.42 to $9.92. Published first on TheFly – the ultimate...

7d ago

SLS

Sellas Life Sciences put volume heavy and directionally bearish

Bearish flow noted in Sellas Life Sciences (SLS) with 9,677 puts trading, or 3x expected. Most active are...

16d ago

SLS

Sellas Life Sciences presents preclinical data on SLS009 at AACR Conference

SELLAS Life Sciences (SLS) Group announced preclinical data from studies evaluating SLS009, its highly selective cyclin-dependent kinases 9...

28d ago

SLS

SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon

SELLAS Life Sciences stock was a hot topic among retail traders on Monday as the company is getting...

2M ago

SLS

Moderna data bode well for Sellas into imminent readout, says Maxim

Maxim views Moderna’s (MRNA) melanoma mRNA cancer vaccine results this morning as a “win for cancer vaccines.” Sellas...

2M ago

SLS

MRNA

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $35 from...

2M ago

SLS

Sellas Life Sciences options imply 8.0% move in share price post-earnings

Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 2:1. Implied volatility suggests...

2M ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares up 7.39%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares up 74c, or 7.39%, near $10.75. Options volume...

3M ago

SLS

Cboe data shows mixed options sentiment in Sellas Life Sciences with shares down 3.3%

Cboe data shows mixed options sentiment in Sellas Life Sciences (SLS), with shares down 34c near $9.95. Options...

3M ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares down 11.17%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares down $1.21 near $9.62. Options volume running well...

3M ago

SLS

SELLAS Life Sciences Faces Adverse Arbitration Ruling

SELLAS Life Sciences Group ( ($SLS) ) has issued an update. On July 24, 2026, a sole arbitrator...

3M ago

SLS

SELLAS Updates Executive Severance and Change-of-Control Terms

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). On June 24, 2026, SELLAS...

4M ago

SLS

SELLAS Stockholders Approve Governance and Equity Plan Changes

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On June 16, 2026, SELLAS...

4M ago

SLS

SLS FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?

SELLAS Life Sciences Group lowest stock price was $1.39 and its highest was $15.88 in the past 12 months.

What is SELLAS Life Sciences Group’s market cap?

SELLAS Life Sciences Group’s market cap is $2.42B.

When is SELLAS Life Sciences Group’s upcoming earnings report date?

SELLAS Life Sciences Group’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.

How were SELLAS Life Sciences Group’s earnings last quarter?

SELLAS Life Sciences Group released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.045 by -$0.005.

Is SELLAS Life Sciences Group overvalued?

According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SELLAS Life Sciences Group pay dividends?

SELLAS Life Sciences Group does not currently pay dividends.

What is SELLAS Life Sciences Group’s EPS estimate?

SELLAS Life Sciences Group’s EPS estimate is -0.05.

How many shares outstanding does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group has 201,945,710 shares outstanding.

What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?

SELLAS Life Sciences Group reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.045. Following the earnings report the stock price went up 6.516%.

Which hedge fund is a major shareholder of SELLAS Life Sciences Group?

Currently, no hedge funds are holding shares in SLS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SELLAS Life Sciences Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.91%

Trailing 12-Months

Asset Growth

350.03%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group (SLS) Earnings & Revenues

Historic Earnings Reports

SLS Stock 12 Month Forecast

Average Price Target

$30.00

▲(112.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","31":"$31","7.75":"$7.75","15.5":"$15.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7.75,15.5,23.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,12.766153846153847,14.202307692307693,15.638461538461538,17.074615384615385,18.51076923076923,19.946923076923078,21.383076923076924,22.81923076923077,24.255384615384617,25.691538461538464,27.12769230769231,28.563846153846157,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,12.766153846153847,14.202307692307693,15.638461538461538,17.074615384615385,18.51076923076923,19.946923076923078,21.383076923076924,22.81923076923077,24.255384615384617,25.691538461538464,27.12769230769231,28.563846153846157,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,12.766153846153847,14.202307692307693,15.638461538461538,17.074615384615385,18.51076923076923,19.946923076923078,21.383076923076924,22.81923076923077,24.255384615384617,25.691538461538464,27.12769230769231,28.563846153846157,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.27,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >